Mini ReviewVolume 2 Issue 4 - August 2017DOI: 10.19080/NAPDD.2017.02.555592

Nov Appro Drug Des DevCopyright © All rights are reserved by Asit Kumar Chakraborty

Enzybiotics, A New Class of Enzyme Antimicrobials Targeted against Multidrug-Resistant Superbugs

Asit Kumar Chakraborty*Department of Biochemistry and Biotechnology, Vidyasagar University, India

Submission: August 07, 2017; Published: August 30, 2017

*Corresponding author: Asit Kumar Chakraborty, Department of Biochemistry and Biotechnology, OIST, Vidyasagar University, West Bengal, Midnapore 721102, India, Tel: ; Email:

Introduction

The term enzibiotic was coined from two words, enzyme and antibiotic and usually refers as the bacteriophage enzymes that attack the cell wall of bacteria with lyses [1]. However, enzybiotic present in bacteria, bacteria infected phages and in body fluids like tears, saliva and animal mucous [2]. Antibiotics had used 80 years with success to eradicate pathogenic bacteria like Escherichia, Klebsiella, Salmonella, Mycobacterium, Pseudomonas and Vibrio species. However, last two decades gradual increase of clinical isolates had shown with >95% now ampicillin and amoxicillin resistant which was controlled by synthesis of new derivatives of penicillin like cephalosporin and carbapenem drugs [3]. In 2009 NDM-1 Escherichia coli was found however, resistant to all class of penicillins including Beta-lactamase inhibitors like cavulinate and sulbactam but avibactam [4]. Skin infections by MRSA Staphylococcus aureus, PDR nosocomial infections by Pseudomonas aeroginosa and XDR tuberculosis by Mycobacterium tuberculosis are now serious threat to human and alternative approaches should be needed to overcome such crisis [5]. MDR genes (blaTEM, amp, blaNDM, blaOXA, sul1/2, catB3, aacA4, aacC2, aph, aad, dhfr, arr3,strA/B,

etc) and drug efflux genes (tetA, acrAB-TolC, mexAB-oprM, mcr, macAB, norA, mdtA etc.) are wide spread in conjugative plasmids and chromosomes of superbugs which are also found in rain, sea and river water posing a threat to global peoples [6].

Thus a new field of science is enzybiotics which is under clinical trial in many research foundations. If enzybiotic is injected into patient with success then all physicians believe that such single enzyme or chimera enzyme would be most useful in superbug cure [7]. It is to save gut microbiota that provide life saving coenzymes involved in glycosysis, TCA cycle and ATP generation [5].

Result

Some important enzybiotics are:

(a) Lysins. PlyG is Phage-γ amidase which can destroy Bacillus anthracis (Figure 1) [8].

(b) Bacteriocins. Lysostaphin is Streptococcus simulans enzyme that acts as endopeptidase on Staphylococcus aureus and many Streptococcei sp. (Figure 2) [9].

Nov Appro Drug Des Dev 2(4): NAPDD.MS.ID.555592 (2017) 001

Abstract

Gut microbiota with 2X1012 bacterial populations is essential for synthesis of vitamins, coenzymes and many other biomolecules in human and animal. But high dose of antibiotics destructed (since 1928) such bacteria in the alimentary tract posing a threat to extinct of human life. As a result signalling from human and bacteria orchestrated to build a defence to protect symbiotic relations saving both life forms. Bacteria synthesized hundreds of new genes (MDR Genes) to destroy antibiotics in different modes of actions. G-20 leaders and scientists have vowed a strong action plans (as assembled recently in Germany) to abolish the horror of superbugs which are claiming millions of death worldwide. Enzymes as therapeutic antibiotics has taken as emerging new antimicrobials derived from bacteriophages as well as bacteria like Staphylococcus sp., Streptococcus sp. and Histeria monocytogenes. Simply, autolysins, lysozymes, lysins and bacteriocins are great enzybiotics. Genetically modified enzybiotic (GMEnzy) has now a new field of enzyme antibiotic production using molecular biology and genetic engineering principles to overcome the antibiotic resistance. GMEnzy database has built for researchers and is available at http://biotechlab.fudan.edu.cn/database/gmenzy/.

How to cite this article: Chakraborty AK. Enzybiotics, A New Class of Enzyme Antimicrobials Targeted against Multidrug-Resistant Superbugs. Nov Appro Drug Des Dev. 2017; 2(4) : 555592. DOI: 10.19080/NAPDD.2017.02.555592.002

Novel Approaches in Drug Designing & Development

Figure 1: Primary amino acid sequence of lysins/holins muramidase.

Figure 2: Primary amino acid sequence of a bacteriocin/HlyD type.

Figure 3: Primary amino acid sequence of a Staphylococcus aureus autolysin.

(c) Autolysins. S. equidermis autolysin enzyme lyses β (1->4) glycoside bong between N-acetyl glucosamine and N-acetyl muraminic acid of many bacteria (Figure 3) [10].

(d) Lysozymes. Egg white lysozyme is muramidase that destroy peptidoglycans and very effective against Gram (+) bacteria [11].

How to cite this article: Chakraborty AK. Enzybiotics, A New Class of Enzyme Antimicrobials Targeted against Multidrug-Resistant Superbugs. Nov Appro Drug Des Dev. 2017; 2(4) : 555592. DOI: 10.19080/NAPDD.2017.02.555592.003

Novel Approaches in Drug Designing & Development

The lysins are 453-473aa long extracellular enzymes and have been sequenced from Streptococcus suis, Streptococcus agalactiae and others (protein ids. WP_061713285, WP_043026720, WP_070043600) with 50-150 mutations among themselves [12,13]. The multispecies bacteriocin (protein id. WP_013103375) has only 54% amino acid similarities to the Leuconostoc sp. Bacteriocin secretory protein (protein id. WP_030058663) but further pharmacological data are lacking. Autolysins are also much diverged as S. aureus enzyme (protein id. AAA99982; accession no. L41499) has only 60% homology with 8% gap to other autolysin enzymes (protein id. BAD83399) [14]. Genetically recombinant Lysins have great potential in curing MDR-bacteria [15-18]. P2neumococcal LytA autolysin, a potent therapeutic agent in peritonitis-sepsis caused by highly beta-lactamase resistant Streptococcus pneumonia [19,20].

Discussion

Enzybiotics is an emerging field of medicinal science with many molecular approaches have undertaken which have patent litigations and many data are hidden from GenBank database now [13]. It also has combined with phage therapy technologies targeting both Gram (+) and Gram (-) bacterial pathogenesis originating from MDR genes of superbugs [10]. We believe as MDR genes are created both from human and bacteria symbiosis, it will be there with gut microbiota [5]. So to eliminate the pathogenic bacteria alternative to antibiotics will be forthcoming like gene medicines (antisense, Casper-Cas, SiRNA, miRNA, ribozyme) and nanodrug-carriers [21]. Thus enzybiotic is in good place in molecular medicine and its success is ahead. Novel chimerical endolysins with broad antimicrobial activity against methicillin-resistant Staphylococcus aureus was reported [16,22]. About 1144 enzybiotics along with 216 natural resources (heterogeneous phyto-antibiotics) have been listed in GMEnzy database [2,13,23,24].

References1. Borysowaski J, Gorski A (2010) Enzybiotics and their potential

application in medicine. In: Villa Tg, Veiga Crespo P (Eds.), Enzybiotics: antibiotic enzymes as drugs and therapeutics. (11th edn), John Wiley & Sons Inc. Publication, New Jersy, USA, pp. 199-218.

2. Wu H, Huang J, Lu H, Li G, Huang Q (2014) GMEnzy: A genitically modified enzymatic database. PLoS One 9(8):e103687.

3. Chakraborty AK (2017) Mechanism of AMR: Mdr genes and antibiotics decoys retard the new antibiotic discovery against superbugs. Nov Appro Drug Des Dev 2(1): 555576.

4. Chakraborty AK (2016) In silico analysis of hotspot mutations in the bacterial NDM-1 and KPC-1 carbapenemases that cause severe MDR phenotypes. Biochem Biotechnol Res 4(1): 17-26.

5. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, et al. (2013) Richness of human gut microbiome correlates with metabolic markers. Nature 500(7464): 541-546.

6. Chakraborty AK (2016) Multi-drug resistant genes in bacteria and 21st Century problems associated with antibiotic therapy. Biotechnol Ind J 12(12): 113.

7. Thallinger B, Prasetyo EN, Nyanhongo GS, Guebitz GM (2013) Antimicrobial enzymes: an emerging strategy to fight microbes and microbial biofilms. Biotechnol J 8(1): 97-109.

8. Yang H, Zhang Y, Yu J, Huang Y, Zhang XE, et al. (2014) A novel chimeric lysine with high antimicrobial activity against methicillin-resistant Staphylococcus aureus in vitro and in vivo. Antimicrob Agents Chemother. 58(1): 536-542.

9. Manoharadas S, Witte A, Bläsi U (2009) Antimicrobial activity of chimeric enzybiotic towards S. Aureus. J Biotechnol 139(1): 118-128.

10. Hermoso JA, García JL, García P (2007) Taking aim on bacterial pathogens: from phage therapy to enzybiotics. Curr Opin Microbiol 10(5): 461-472.

11. Foster SJ (1995) Molecular characterization and functional analysis of the major autolysin of Staphylococcus aureus 8325/4. J Bacteriol 177(19): 5723-5725.

12. Becker SC, Foster-FJ, Donovan DM (2008) The phageK lytic enzyme LysK and lysostaphin act synergistically to kill MRSA. FEMS Microbiol Lett 287(2): 185-191.

13. Hojckova K, Stano M, Klucar L (2013) Phibiotics: Catalogue of therapeutic enzybiotics relevant research studies and practical applications. BMC Microbiol 13: 53.

14. Rashel M, Uchiyama J, Ujihara T, Uehara Y, Kuramoto S, et al. (2007) Efficent elimination of multidrug-resistant S. aureus by cloned Lysin derived from bacteriophage Phi MR11. J Infect Dis 196(8): 1237-1247.

15. Veiga-CP, Ageitos JM, Poza M, Villa TG (2007) Enzybiotics: a look to the future, Recalling the past. J Pharm Sci 96(8): 1917-1924.

16. Nelson DC, Schmelcher M, Rodriguez-RL, Klumpp J, Pritchard DG, et al. (2012) Endolysins as antibacterials. Adv Virus Res 83: 299-365.

17. Yokoi KJ, Kawahigashi N, Uchida M, Sugahara K, Shinohara M, et al. (2005) The two-component cell lysis genes holWMY and lysWMY of the Staphylococcus warneri M phage varphiWMY: cloning, sequencing, expression, and mutational analysis in Escherichia coli. Gene 351: 97-108.

18. Fenton M, Ross P, McAuliffe O, O Mahony J, Coffey A (2010) Recombinant bacteriophage Lysins as antibacterials. Bioeng Bugs 1(1): 9-16.

19. Maestro B, Sanz JM (2016) Choline binding proteins from Streptococcus pneumoniae: A dual role as enzybiotics and targets for the design of new antimicrobials. Antibiotics (Basel) 5(2): 21.

20. Rodríguez-CV, García P, Huelves L, García E, Del Prado G, et al. (2007) Pneumococcal LytA autolysin, a potent therapeutic agent in peritonitis-sepsis caused by highly brta-lactamase resistant Streptococcus pneumonia. Antimicrob Agents Chemother 51(9): 3371-3373.

21. Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, et al. (2013) One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 154(6): 1370-1379.

22. Fernandes S, Proença D, Cantante C, Silva FA, Leandro C, et al. (2012) Novel chimerical endolysins with broad antimicrobial activity against methicillin-resistant Staphylococcus aureus. Microb Drug Resist 18: 333-343.

23. Yang H, Li J, Shin HD, Du G, Liu L, Chen J (2014) Molecular engineering of industrial enzymes: recent advances and future prospects. Appl Microbiol Biotechnol 98(1): 23-29.

24. Chakraborty AK (2017) Multi-drug resistant bacteria from Kolkata Ganga river with heterogeneous MDR genes have four hallmarks of cancer cells but could be controlled by organic phyto-extracts. Biochem Biotechnol Res 5(1): 11-23.

How to cite this article: Chakraborty AK. Enzybiotics, A New Class of Enzyme Antimicrobials Targeted against Multidrug-Resistant Superbugs. Nov Appro Drug Des Dev. 2017; 2(4) : 555592. DOI: 10.19080/NAPDD.2017.02.555592.004

Novel Approaches in Drug Designing & Development

This work is licensed under CreativeCommons Attribution 4.0 LicensDOI: 10.19080/NAPDD.2017.02.555592.

Your next submission with Juniper Publishers will reach you the below assets

• Quality Editorial service• Swift Peer Review• Reprints availability• E-prints Service• Manuscript Podcast for convenient understanding• Global attainment for your research• Manuscript accessibility in different formats

( Pdf, E-pub, Full Text, Audio) • Unceasing customer service

Track the below URL for one-step submission https://juniperpublishers.com/online-submission.php